CN1988901A - 用于治疗肿瘤疾病和炎症的药物制品 - Google Patents
用于治疗肿瘤疾病和炎症的药物制品 Download PDFInfo
- Publication number
- CN1988901A CN1988901A CNA2005800253911A CN200580025391A CN1988901A CN 1988901 A CN1988901 A CN 1988901A CN A2005800253911 A CNA2005800253911 A CN A2005800253911A CN 200580025391 A CN200580025391 A CN 200580025391A CN 1988901 A CN1988901 A CN 1988901A
- Authority
- CN
- China
- Prior art keywords
- ingredient
- tocotrienol
- flavonoid
- functional food
- suffering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 22
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 4
- 201000010099 disease Diseases 0.000 title abstract description 3
- 230000001613 neoplastic effect Effects 0.000 title abstract description 3
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 229930003935 flavonoid Natural products 0.000 claims abstract description 44
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 44
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 44
- 229930003802 tocotrienol Natural products 0.000 claims abstract description 38
- 239000011731 tocotrienol Substances 0.000 claims abstract description 38
- 235000019148 tocotrienols Nutrition 0.000 claims abstract description 38
- 239000004615 ingredient Substances 0.000 claims abstract description 34
- 235000013376 functional food Nutrition 0.000 claims abstract description 33
- 239000013543 active substance Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 235000020971 citrus fruits Nutrition 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 8
- 239000002398 materia medica Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 241001047198 Scomberomorus semifasciatus Species 0.000 claims description 4
- 235000012467 brownies Nutrition 0.000 claims description 4
- 235000014510 cooky Nutrition 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 235000019219 chocolate Nutrition 0.000 claims description 3
- 235000020166 milkshake Nutrition 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 235000013310 margarine Nutrition 0.000 claims description 2
- 239000003264 margarine Substances 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 235000021147 sweet food Nutrition 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims 1
- 235000013365 dairy product Nutrition 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 abstract description 2
- 229940068778 tocotrienols Drugs 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 8
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 240000000560 Citrus x paradisi Species 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 5
- 239000004410 anthocyanin Substances 0.000 description 5
- 229930002877 anthocyanin Natural products 0.000 description 5
- 150000004636 anthocyanins Chemical class 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 4
- 241000207199 Citrus Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 4
- 229920001991 Proanthocyanidin Polymers 0.000 description 4
- 244000291414 Vaccinium oxycoccus Species 0.000 description 4
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 150000002630 limonoids Chemical class 0.000 description 4
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- -1 polyphenol compound Chemical class 0.000 description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 3
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 3
- 229940064063 alpha tocotrienol Drugs 0.000 description 3
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 3
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 3
- 235000010209 hesperetin Nutrition 0.000 description 3
- 229960001587 hesperetin Drugs 0.000 description 3
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 3
- 208000012804 lymphangiosarcoma Diseases 0.000 description 3
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 3
- 235000007625 naringenin Nutrition 0.000 description 3
- 229940117954 naringenin Drugs 0.000 description 3
- 235000008603 tangeritin Nutrition 0.000 description 3
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 235000019145 α-tocotrienol Nutrition 0.000 description 3
- 239000011730 α-tocotrienol Substances 0.000 description 3
- 235000019150 γ-tocotrienol Nutrition 0.000 description 3
- 239000011722 γ-tocotrienol Substances 0.000 description 3
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 3
- 235000019144 δ-tocotrienol Nutrition 0.000 description 3
- 239000011729 δ-tocotrienol Substances 0.000 description 3
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 235000007716 Citrus aurantium Nutrition 0.000 description 2
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 235000016646 Citrus taiwanica Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- ZIKZPLSIAVHITA-UHFFFAOYSA-N Nomilinic acid Natural products CC(=O)OC(CC(O)=O)C1(C)C(C(C)(C)O)CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 ZIKZPLSIAVHITA-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000007946 flavonol Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 2
- FYIKIBQJAJRKQM-WNCNYDOCSA-N limonin 17-beta-D-glucoside Chemical compound O([C@H]([C@@]1(CC[C@H]2[C@@]([C@@]11[C@H](O1)C(O)=O)(C)C(=O)C[C@@H]1[C@]32COC(=O)C[C@@H]3OC1(C)C)C)C1=COC=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FYIKIBQJAJRKQM-WNCNYDOCSA-N 0.000 description 2
- FYIKIBQJAJRKQM-UHFFFAOYSA-N limonoid glycoside Natural products CC1(C)OC2CC(=O)OCC22C1CC(=O)C(C13C(O3)C(O)=O)(C)C2CCC1(C)C(C1=COC=C1)OC1OC(CO)C(O)C(O)C1O FYIKIBQJAJRKQM-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- KPDOJFFZKAUIOE-WNGDLQANSA-N nomilin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@H]2C(C)(C)OC(=O)C[C@@H]([C@]42C)OC(=O)C)C=COC=1 KPDOJFFZKAUIOE-WNGDLQANSA-N 0.000 description 2
- KPDOJFFZKAUIOE-HPFWCIFASA-N nomilin Natural products O=C(O[C@H]1[C@@]2(C)[C@@H](C(C)(C)OC(=O)C1)CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@H](c3cocc3)OC(=O)[C@@H]3O[C@@]123)C KPDOJFFZKAUIOE-HPFWCIFASA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229940060037 fluorine Drugs 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical class [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明的某些具体实施方案中公开的是包含药物成分和至少一种药物学可接受的赋形剂的药物制剂或功能性食品以及用于治疗肿瘤疾病和炎症的方法，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合。
Description
相关申请
本申请要求于2004年5月26日提交的美国临时申请No.60/574,487的优先权，其并入此处作为参考。
技术领域
本发明涉及包含类黄酮(flavonoids)和生育三烯酚的组合物以及治疗癌症和炎症的方法。
背景技术
在美国，癌症是继心脏病之后导致死亡的第二大因素(Boring，C.C.等，1993，CA Cancer J.Clin.43：7)，且三分之一的美国人患有癌症，四分之一的美国人死于癌症。癌症可以看作是肿瘤细胞与它们的环境，包括其正常的邻近细胞之间的通讯障碍。刺激生长和抑制生长的信号均在组织内的细胞之间例行地交换。通常，细胞在没有刺激信号时并不分裂，同样地，在抑制信号存在的情况下会停止分裂。在癌变或肿瘤状态中，细胞获得了“无视”这些信号并在正常细胞不生长的条件下增殖的能力。除了无休止的细胞增殖之外，细胞必须获得若干特性肿瘤才能生长。例如，在肿瘤发展早期，细胞必须逃避宿主免疫系统。此外，随着肿瘤质量增长，肿瘤必须获得脉管系统以提供养料并除去代谢废物。另外，细胞必须获得侵袭邻近组织的能力，并且最终细胞通常获得向远距离的部位转移的能力。
乳腺癌是西方世界女性中最常见的恶性疾病形式，也是年龄在40和45岁之间的女性的最常见的死因。
在北美洲女性中，与将患乳腺癌的危险提高三到四倍相关的特征包括：(1)曾经患有乳腺癌的一级(first-degree)女性家庭成员(母亲和姐妹)、(2)先前患有乳腺癌、(3)未生育过、(4)首次妊娠年龄大于30岁、(5)早月经初潮或晚绝经(Sattin，R.W.等，1985，JAMA253：1908)。国际研究表明，人均脂肪和酒精消耗量(Schatzkin A.等，1987，N.Engl.J.Med.316：1169)与乳腺癌的发病率成正相关。(Carroll，K.K.，1980，J.Env.Pathol.Tox.3：253-271)。若干研究将食用新鲜水果蔬菜和维生素E与癌症的发生的风险降低联系起来(Steinmetz，K.A.等，1991，Cancer Causes Control 2：427-442)。尽管通常认为，这些保护作用是由于这些食物中存在的维生素C和β-胡萝卜素的抗氧化作用，但是还可能将其与其它植化成分相关联，例如，柑桔柠檬苦素类化合物(citrus limonoid)和类黄酮。单独使用柠檬苦素类化合物、类黄酮或生育三烯酚类，或彼此或与化疗药物联合使用用于肿瘤疾病的预防和治疗均未见报道。
本发明提供多种不同的包括但不限于柠檬苦素(limonin)、诺米林(nomilin)、柠檬苦素糖苷(limonin glucoside)或糖苷混合物的柑桔柠檬苦素类化合物，包括川陈皮素(nobiletin)或红橘素(tangeretin)的类黄酮，以及包括α-生育三烯酚、γ-生育三烯酚或δ-生育三烯酚的生育三烯酚。
可以通过本发明的组合物和方法预防和/或治疗的癌症包括，但不仅限于：人类肉瘤和癌，例如，癌，如结肠癌、胰腺癌、乳腺癌、卵巢癌、前列腺癌、纤维肉瘤、粘液肉瘤、脂肪肉瘤、软骨肉瘤、骨源性肉瘤(osteogenic sarcoma)、软骨瘤、血管肉瘤、内皮肉瘤(endotheliosarcoma)、淋巴管肉瘤(lymphangiosarcoma)、淋巴管内皮肉瘤(lymphangio-endotheliosarcoma)、滑膜瘤、间皮瘤、尤因瘤(Ewing′s tumor)、平滑肌肉瘤、横纹肌肉瘤、鳞状细胞癌、基底细胞癌、腺癌、汗腺癌、皮脂腺癌、乳头状癌(papillary carcinoma)、乳头状腺癌(papillaryadenocarcinomas)、囊腺癌、髓样癌、支气管癌、肾细胞癌、肝癌、胆管癌、绒毛膜癌、精原细胞瘤、胚胎癌、Wilms’瘤、子宫颈癌、睾丸肿瘤(testicular tumor)、肺癌、小细胞肺癌、膀胱癌、上皮癌、神经胶质瘤、星形细胞瘤、髓母细胞瘤、颅咽管瘤、室管膜瘤(ependymoma)、松果体瘤、成血管细胞瘤、听神经瘤、少突神经胶质瘤、脑膜瘤、黑素瘤、成神经细胞瘤、视网膜母细胞瘤；白血病，例如，急性淋巴细胞性白血病和急性髓细胞性白血病(原粒细胞性、早幼粒细胞性、骨髓单核细胞性、单核细胞性以及红白血病)、慢性白血病(慢性中幼粒细胞(粒细胞)白血病和慢性淋巴细胞性白血病)；以及真性红细胞增多症、淋巴瘤(霍奇金病和非霍奇金病)、多发性骨髓瘤、瓦尔登斯特伦巨球蛋白血症以及重链病。这些癌症的具体实例如下列段落所述。
炎症通常与以下症状有关：(1)发红、(2)肿胀、(3)发热、(4)疼痛，并可能伴有第五种症状——患处功能受损。尽管损伤引起一系列复杂的事件，其中许多同时发生，并且以各种方式相互关联，但已知小血管在诱发炎症中起到了重要作用。事实上，炎症是机体重要的防御机制之一，并且一般认为有三个阶段：变性阶段(degenerative phase)、血管阶段(vascular phase)和愈合阶段(healing phase)。参见Klein的“DefenseReactions in Action”，Immunology，The Science of Self-NonselfDiscrimination，第14章，577-84(1982)，其公开内容并入此处作为参考。
本发明涉及使用类黄酮和生育三烯酚的组合来预防和治疗肿瘤疾病和/或炎症的组合物和方法。类黄酮是主要(unbiquitiously)存在于植物性食品尤其是橙、葡萄柚、和柑橘中的多酚类化合物。生育三烯酚存在于棕榈油中并且是具有不饱和侧链的一种形式的维生素E。
发明内容
本发明的目的是提供一种包含类黄酮和生育三烯酚的、用于治疗和/或预防肿瘤疾病和/或炎症的药物成分、制剂或功能性食品。
本发明的另一个目的是提供一种通过给药包含类黄酮和生育三烯酚的药物成分、制剂或功能性食品来治疗肿瘤疾病和/或炎症的方法。
本发明的另一个目的是提供一种利用类黄酮和生育三烯酚来治疗肿瘤疾病和/或炎症的药物成分、制剂或功能性食品以及方法，其中所述药物成分、制剂或功能性食品具有低水平的脱氧肾上腺素。
本发明某些上述目的可以通过本发明来实现，其中在某些具体实施方案中本发明涉及包含含有约75∶25到约95∶5比例的多甲氧基化(polymethoxylated)类黄酮和生育三烯酚的活性物质组合的药物成分，所述药物成分选自以下组中：柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油(peel oil)、从柑橘类水果中分离得到的果皮(peel)、改质化(decharacterized)的柑橘类水果、以及其组合。
在某些具体实施方案中，本发明涉及包含药物成分和至少一种药物学可接受的赋形剂的药物制剂或功能性食品，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合。
在某些具体实施方案中，本发明涉及通过给药本文公开的药物成分、制剂或功能性食品来治疗肿瘤疾病和/或炎症的方法。
术语“精油”是指果汁蒸发之后残留的油溶性成分(如，级分(fraction))。
术语“果皮油”是指从柑橘类水果的果皮中分离得到的油。
术语“果皮”是指柑橘类水果的果皮，为了本发明目的，它可以经过例如干燥、切碎或粒化。
术语“柑橘类水果”是指来自柑橘属的水果，包括橙、柠檬、甜柠檬(lime)、柑橘、葡萄柚(如粉红葡萄柚(pink grapefruit)、红皮柚(redpeel grapefruit))以及特别是酸橙(Citrus aurantium)。
术语“改质化的水果”是指已经被榨取果汁的水果。改质化的水果可以采用如浆状物或压榨饼的形式。术语“Tomah压榨饼”是指美国专利No.5,320,861和5,320,861中记载的特别优选的压榨饼，它比通过常规方法制备的压榨饼含有更高水平的所需的植物化学成分。具体而言，采用“Tomah压榨饼”形式的改质化的蔓越橘果实比通过常规方法制备的压榨饼含有更高水平的花色素苷(anthocyanin)、酚酸和原花色素(proanthocyanidin)。例如，花色素苷含量通常占原产蔓越橘果实中含量的30％或更高，酚酸含量通常占原产蔓越橘果实的8％或更高，而原花色素含量通常占原产蔓越橘果实的60％或更高。
术语“分离”是指从其天然环境中去除或改变组分或化合物。
术语“类黄酮”包括但不限于多甲氧基化的类黄酮，是指本发明的衍生物中存在的芳香性、含氧、杂环的色素的组中的任何成员，而且包括例如以下化学亚组中的成员：1)儿茶素、2)白花色素和黄烷酮、3)flavanin、黄酮、和花色素苷、以及4)黄酮醇。在优选的具体实施方案中，类黄酮包括如原花色素、黄烷-3-醇、花色素苷、或黄烷醇。类黄酮可以包括如柚皮素(naringenin)、橙皮素(hesperetin)、川陈皮素、和/或红橘素。
术语“生育三烯酚”是指以可检测水平存在于本发明水果衍生物中的任何生育酚(T)或生育三烯酚(T3)化合物，例如，α-生育酚、γ-生育酚、δ-生育酚、α-生育三烯酚、γ-生育三烯酚、δ-生育三烯酚、或其组合。
术语“药物成分”是指可以任选地与药物学可接受的赋形剂结合以获得药物制剂或剂型的治疗组合物。
术语“药物制剂”是指与至少一种药物学可接受的赋形剂结合的药物成分。该制剂通过任何可接受的途径给药，如以任何可接受的形式如片剂或胶囊通过口服给药。
出于本发明的目的，术语“功能性食品”是用本文公开的类黄酮和生育三烯酚增强或强化的任何可食用的或可饮用的食品或饮食成分(例如果汁、焙烤食品、苹果酱等)。该功能性食品可以是如固体、液体、半固体、或其组合。术语“功能性食品”还涵盖可食用和可饮用的营养补充剂。
具体实施方式
在某些具体实施方案中，本发明涉及包含含有约75∶25到约95∶5比例的多甲氧基化的类黄酮和生育三烯酚的活性物质组合的药物成分，该药物成分选自以下组中：从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果分离得到的果皮、改质化的柑橘类水果、以及其组合。
在某些具体实施方案中，该活性物质组合含有约90∶10比例、约80∶20比例、或约95∶5比例的类黄酮和生育三烯酚。
在某些具体实施方案中，本发明的药物成分含有约50％到约90％的类黄酮和生育三烯酚、约60％到约80％的该活性物质组合、或约70％的该活性物质组合。
在某些具体实施方案中，该药物成分含有低于约1％的脱氧肾上腺素、低于约0.5％的脱氧肾上腺素、或低于0.1％的脱氧肾上腺素。
本发明的类黄酮可以是多甲氧基化的类黄酮。在某些具体实施方案中，该类黄酮包含选自以下组中的成员：柚皮素、橙皮素、川陈皮素、红橘素及其组合。
本发明的生育三烯酚可以例如选自以下组中：α-生育三烯酚、γ-生育三烯酚、δ-生育三烯酚及其组合。
在某些具体实施方案中，本发明涉及包含药物成分和至少一种药物学可接受的赋形剂的药物制剂或功能性食品，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合。
在某些具体实施方案中，本发明的药物制剂或功能性食品包含选自以下组中药物成分：从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果、以及其组合。
在某些具体实施方案中，本发明制剂所包含的药物成分是以治疗具有患肿瘤疾病和/或炎症的风险或患有肿瘤疾病和/或炎症的人类对象有效的量存在。
在某些具体实施方案中，本发明的药物制剂适于静脉内、腹膜内、皮下、肌肉内、鞘内(intrathecally)、口服、直肠、局部或通过吸入给药。
在某些具体实施方案中，本发明的药物制剂是采用片剂、胶囊、溶液、液体、混悬剂或乳剂的形式。
在其中本发明是采用功能性食品的形式的某些具体实施方案中，该功能性食品是采用可食用或可饮用的组合物的形式，例如食品如可咀嚼的或可食用的棒状食品、甜食(如巧克力棒)、曲奇、果汁饮料、焙烤或仿焙烤的商品(如布朗尼(brownie))、饼干、锭剂、或口香糖。优选的可咀嚼或可食用的棒状食品包括巧克力棒和布朗尼。这种食品因提供了如上所述的类黄酮和生育三烯酚的好处并且还提供了缓解饥饿或疲劳的好处从而是有益的。这种功能性食品对参与运动或其他形式的锻炼的人特别有益。
该功能性食品还可采用如黄油、人造黄油、面包、蛋糕、奶昔冰淇淋(milk shakes)、冰淇淋、酸奶酪和其他发酵牛奶制品的形式。
该功能性食品还可以采用用于撒在肉类、色拉或其它食物上的粉末的形式。它们可以并入固体食物如块状糖(candy bars)、谷类、健康棒状食品(health bar)和其他食物中。
其他形式的功能性食品可以是早餐谷类如谷片(grain flake)或穆兹利(muesli)。
在某些具体实施方案方案中，本发明的药物制剂或功能性食品每单位剂量包含约60mg的生育三烯酚和约560mg的类黄酮；每单位剂量约10mg到约80mg的生育三烯酚以及约150mg到约750mg的类黄酮；或者每单位剂量约30mg的生育三烯酚和约270mg的类黄酮。
在本发明的方法中，活性物质的每日剂量可以是例如约60mg的生育三烯酚和约560mg的类黄酮、约10mg到约80mg的生育三烯酚和约150mg到约750mg的类黄酮、或约30mg的生育三烯酚和约270mg的类黄酮。
在本发明的方法中，类黄酮和生育三烯酚可以相同的剂型或功能性食品给药，或者以单独的剂型或功能性食品给药。此外，类黄酮和生育三烯酚可以相同的给药途径或不同的给药途径给药。
本发明的药物制剂可以制备成口服、舌下、吸入、皮下、肌肉内、静脉内、透皮制剂、以及用于局部或直肠给药的制剂。口服制剂可以采用如片剂、凝胶胶囊(gel capsule)、散剂、颗粒剂以及口服溶液或混悬剂、舌下和含服给药的形式。
当固体组合物制备成片剂或凝胶胶囊时，可以将药物赋形剂的混合物加入到微粉化或非微粉化的活性成分中，所述药物赋形剂的混合物可包含稀释剂如乳糖、微晶纤维素、淀粉、磷酸二钙，粘合剂如聚乙烯吡咯烷酮、羟丙基甲基纤维素，崩解剂(crumbling agent)如交联聚乙烯吡咯烷酮、交联羧甲基纤维素，助流剂如硅石或滑石，以及润滑剂如硬脂酸镁、硬脂酸、三山嵛酸甘油脂或硬脂酰富马酸钠。
润湿剂或表面活性剂如十二烷基硫酸钠、聚山梨醇酯80或泊洛沙姆188可以加入到该制剂中。
片剂可通过各种不同的技术制备：直接压片、干法制粒、湿法制粒、热熔法。
该片剂可以无包衣包衣(例如，用蔗糖)或用各种聚合物(如羟丙基甲基纤维素)或其他适当的材料包衣。
该片剂通过制备骨架或通过利用包衣可以速释、延迟释放或缓释。
该凝胶胶囊可以是软的或硬的，并用薄膜包衣或未包衣，从而具有速释、延迟释放或缓释活性(如经肠溶形式)。
口服制剂还可以制备成液体或半固体制剂，例如糖浆剂或酏剂形式的制剂可以包含活性成分与优选为不含卡路里的甜味剂的甜味剂、防腐剂羟苯甲酸甲酯和羟苯甲酸丙酯以及矫味剂和适当的着色剂。
水可分散的散剂或颗粒剂可以包含活性成分与分散剂、润湿剂或助悬剂如聚乙烯吡咯烷酮以及甜味剂或香味增强剂的混合物。
对于直肠给药，使用以在直肠温度下熔化的粘合剂如可可脂或聚乙二醇制备的栓剂。
含有药理学相容性分散剂和/或增溶剂如丙二醇的水性混悬液、等渗盐溶液或无菌可注射溶液用于非胃肠道给药或鼻内给药。
因此，为了制备可静脉注射的水溶液，可以使用共溶剂例如醇，如乙醇，或二醇，如聚乙二醇或丙二醇，以及亲水性表面活性剂如聚山梨醇酯80或泊洛沙姆188。为了制备用于肌肉内给药的可注射油性溶液，可以将活性成分用甘油三酯或甘油酯溶解。
乳膏、软膏、凝胶、透皮贴剂以及喷雾剂可用于局部给药。采用其中活性成分可以是醇溶液形式的多层或储库形式的贴剂以及喷雾剂可以用于透皮给药。
包含如三油酸脱水山梨醇酯或油酸以及三氯氟甲烷、二氯氟甲烷、二氯四氟乙烷、氟里昂代用品或其他生物相容性推进气的气雾剂用于通过吸入给药；也可以使用单独包含活性成分或与赋形剂结合的粉末形式的系统。
该活性成分还可以任选地与一种或多种支持物或添加剂配制成微囊或微球的形式。
在可用于慢性治疗的缓释形式中，可使用植入剂。它们可以制备成在等渗介质中的油性混悬剂或者微球混悬剂的形式。
Claims (23)
1、一种包含药物成分和至少一种药物学可接受的赋形剂的药物制剂，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合，其中所述药物成分是以治疗具有患肿瘤疾病的风险或患有肿瘤疾病的人类对象有效的量存在。
2、一种包含药物成分和至少一种药物学可接受的赋形剂的药物制剂，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合，其中所述药物成分是以治疗具有患炎症的风险或患有炎症的人类对象有效的量存在。
3、权利要求1或2的药物制剂，其中所述药物成分选自以下组中：从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果、以及其组合。
4、权利要求1或2的药物制剂，其中所述制剂适于静脉内、腹膜内、皮下、肌肉内、鞘内、口服、直肠、局部或通过吸入给药。
5、如权利要求4的药物制剂，其中所述制剂适于口服给药。
6、如权利要求5的药物制剂，其中所述制剂是以片剂、胶囊、凝胶胶囊、溶液、液体、混悬剂或乳剂的形式存在。
7、如权利要求1或2的药物制剂，其每单位剂量包含约10mg到约80mg的生育三烯酚和约150mg到约750mg的类黄酮。
8、如权利要求1或2的药物制剂，其每单位剂量包含约30mg的生育三烯酚和约270mg的类黄酮。
9、如权利要求1或2的药物制剂，其每单位剂量包含约60mg的生育三烯酚和约560mg的类黄酮。
10、一种包含可食用的固体或液体、药物成分、以及至少一种药物学可接受的赋形剂的功能性食品，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合，其中所述药物成分是以治疗具有患肿瘤疾病的风险或患有肿瘤疾病的人类对象有效的量存在。
11、一种包含可食用的固体或液体、药物成分、以及至少一种药物学可接受的赋形剂的功能性食品，所述药物成分包含含有约75∶25到约95∶5比例的类黄酮和生育三烯酚的活性物质组合，其中所述药物成分是以治疗具有患炎症的风险或患有炎症的人类对象有效的量存在。
12、如权利要求10或11的功能性食品，其中所述药物成分选自以下组中：从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果、以及其组合。
13、如权利要求10或11的功能性食品，其每份(serving)包含约10mg到约80mg的生育三烯酚和约150mg到约750mg的类黄酮。
14、如权利要求10或11的功能性食品，其每份包含约30mg的生育三烯酚和约270mg的类黄酮。
15、如权利要求10或11的功能性食品，其每份包含约60mg的生育三烯酚和约560mg的类黄酮。
16、如权利要求10或11的功能性食品，其为可咀嚼或可食用的棒状食品、甜食、曲奇、果汁饮料、酱状物(puree)、焙烤或仿焙烤的商品、饼干、锭剂、或口香糖的形式。
17、如权利要求10或11的功能性食品，其为布朗尼和巧克力棒的形式。
18、如权利要求10或11的功能性食品，其为黄油、人造黄油、面包、蛋糕、奶昔冰淇淋、冰淇淋、酸奶酪和其他发酵的牛奶产品的形式。
19、如权利要求10或11的功能性食品，其为粉末或谷类的形式。
20、一种治疗具有患肿瘤疾病的风险或患有肿瘤疾病的人类对象的方法，其包括给药有效量的如权利要求1或3-9中任意一项的药物制剂。
21、一种治疗具有患炎症的风险或患有炎症的人类对象的方法，其包括给药有效量的如权利要求2-9中任意一项的药物制剂。
22、一种治疗具有患肿瘤疾病的风险或患有肿瘤疾病的人类对象的方法，其包括给药有效量的如权利要求10或12-19中任意一项的功能性食品。
23、一种治疗具有患炎症的风险或患有炎症的人类对象的方法，其包括给药有效量的如权利要求11-19中任意一项的功能性食品。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57448704P | 2004-05-26 | 2004-05-26 | |
| US60/574,487 | 2004-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1988901A true CN1988901A (zh) | 2007-06-27 |
Family
ID=35450642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800253911A Pending CN1988901A (zh) | 2004-05-26 | 2005-05-24 | 用于治疗肿瘤疾病和炎症的药物制品 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20060013902A1 (zh) |
| EP (1) | EP1748775A4 (zh) |
| JP (1) | JP2008500322A (zh) |
| KR (1) | KR20070088326A (zh) |
| CN (1) | CN1988901A (zh) |
| AU (1) | AU2005247159B2 (zh) |
| CA (1) | CA2567959A1 (zh) |
| IL (1) | IL179473A0 (zh) |
| WO (1) | WO2005115376A1 (zh) |
| ZA (1) | ZA200610170B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200610167B (en) * | 2004-05-26 | 2008-07-30 | Kgksynergize Inc | Functional foods comprising flavonoids and tocotrienols and methods thereof |
| KR20070088325A (ko) * | 2004-05-26 | 2007-08-29 | 케이지케이 시너자이즈 인코포레이티드 | 플라보노이드 및 토코트리에놀을 포함하는 조성물 및그에따른 방법 |
| US20070042972A1 (en) * | 2005-05-24 | 2007-02-22 | Mckeever Kenneth H | Compositions and methods for optimizing exercise recovery |
| MY154376A (en) * | 2006-02-13 | 2015-06-15 | Malaysian Palm Oil Board Mpob | A transdermal fluid |
| US20100196577A1 (en) * | 2009-02-03 | 2010-08-05 | Tropicana Products, Inc. | Microencapsulated citrus phytochemicals comprising citrus limonoids and application to sports drinks |
| US20100196549A1 (en) * | 2009-02-03 | 2010-08-05 | Tropicana Products, Inc. | Microencapsulated citrus phytochemicals and application to sports drinks |
| US20110293753A1 (en) * | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
| US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
| JP6189803B2 (ja) * | 2014-07-30 | 2017-08-30 | 株式会社イムダイン | 経口投与される育毛および頭皮改善剤 |
| JP7458990B2 (ja) | 2018-12-12 | 2024-04-01 | 森永乳業株式会社 | ポリメトキシフラボノイドの溶解性向上方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251400B1 (en) * | 1997-09-26 | 2001-06-26 | Kgk Synergize Inc | Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols |
| US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| US20010055627A1 (en) * | 1997-09-26 | 2001-12-27 | Najla Guthrie | Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols |
| KR20000019716A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 |
| US6987125B1 (en) * | 1998-10-06 | 2006-01-17 | The United States Of America As Represented By The Secretary Of Agriculture | Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones |
| JP3406243B2 (ja) * | 1999-04-12 | 2003-05-12 | 有限会社お菓子のピエロ | 食物アレルギー患者用菓子生地材及びそれを用いた菓子及びその製造方法 |
| US6641847B1 (en) * | 1999-06-01 | 2003-11-04 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
| US6528042B1 (en) * | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| JP2001200238A (ja) * | 2000-01-19 | 2001-07-24 | Pokka Corp | 紫外線吸収剤及びそれを含有した皮膚外用剤 |
| JP2001200237A (ja) * | 2000-01-20 | 2001-07-24 | Pokka Corp | 紫外線吸収剤及びそれを含有した皮膚外用剤 |
| AU2001251610A1 (en) * | 2000-04-13 | 2001-11-07 | Ocean Spray Cranberries, Inc. | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor |
| JP2001346537A (ja) * | 2000-06-07 | 2001-12-18 | Sansei Shokuhin Kk | 果実外皮を用いた機能性食品およびその製造方法 |
| JP2002068956A (ja) * | 2000-08-28 | 2002-03-08 | Nof Corp | 皮膚化粧料 |
| AU2001290165A1 (en) * | 2000-09-15 | 2002-03-26 | Kgk Synergize | Components of canola for the treatment of cancer |
| AU2001290166A1 (en) * | 2000-09-15 | 2002-03-26 | Kgk Synergize | Components of canola for treating hyperlipidemia |
| GB0026018D0 (en) * | 2000-10-24 | 2000-12-13 | Novartis Nutrition Ag | New composition |
| WO2002087567A2 (en) * | 2001-05-02 | 2002-11-07 | Kgk Synergize Inc. | Polymethoxylated flavones for treating insulin resistance |
| US7074825B2 (en) * | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
| WO2005096704A2 (en) * | 2004-04-08 | 2005-10-20 | Kgk Synergize Inc. | Cholesterol lowering composition |
| KR20070088325A (ko) * | 2004-05-26 | 2007-08-29 | 케이지케이 시너자이즈 인코포레이티드 | 플라보노이드 및 토코트리에놀을 포함하는 조성물 및그에따른 방법 |
-
2005
- 2005-05-24 CN CNA2005800253911A patent/CN1988901A/zh active Pending
- 2005-05-24 WO PCT/IB2005/001420 patent/WO2005115376A1/en active Application Filing
- 2005-05-24 KR KR1020067027110A patent/KR20070088326A/ko not_active Application Discontinuation
- 2005-05-24 ZA ZA200610170A patent/ZA200610170B/en unknown
- 2005-05-24 JP JP2007514160A patent/JP2008500322A/ja active Pending
- 2005-05-24 CA CA002567959A patent/CA2567959A1/en not_active Abandoned
- 2005-05-24 EP EP05752904A patent/EP1748775A4/en not_active Ceased
- 2005-05-24 US US11/135,694 patent/US20060013902A1/en not_active Abandoned
- 2005-05-24 AU AU2005247159A patent/AU2005247159B2/en not_active Ceased
-
2006
- 2006-11-21 IL IL179473A patent/IL179473A0/en unknown
-
2008
- 2008-10-13 US US12/250,332 patent/US20090163581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1748775A1 (en) | 2007-02-07 |
| ZA200610170B (en) | 2008-06-25 |
| AU2005247159A1 (en) | 2005-12-08 |
| US20060013902A1 (en) | 2006-01-19 |
| WO2005115376A1 (en) | 2005-12-08 |
| AU2005247159B2 (en) | 2015-07-23 |
| JP2008500322A (ja) | 2008-01-10 |
| US20090163581A1 (en) | 2009-06-25 |
| KR20070088326A (ko) | 2007-08-29 |
| IL179473A0 (en) | 2007-06-03 |
| CA2567959A1 (en) | 2005-12-08 |
| EP1748775A4 (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1988901A (zh) | 用于治疗肿瘤疾病和炎症的药物制品 | |
| Chen et al. | Meta‐analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol | |
| US5453282A (en) | Dietary lipid digestion-absorption inhibitory agents and ingesta | |
| US7452549B2 (en) | Synergistic antioxidant combination of delta tocols and polyphenols | |
| CN101674821B (zh) | 用槲皮素、杨梅黄酮和绿原酸治疗糖尿病和代谢疾病的组合物 | |
| CA2747904C (en) | Compositions and methods for promoting weight loss and increasing energy | |
| IL180740A (en) | Nutritional composition and use thereof in the manufacture of a medicament for treating or preventing osteoporosis | |
| WO2001049285A1 (en) | Flavonoid drug and dosage form, its production and use | |
| US20140050810A1 (en) | Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient | |
| CN1988902A (zh) | 含有类黄酮和生育三烯酚的功能性食品及其方法 | |
| CN101001624A (zh) | 含有类黄酮和生育三烯酚的组合物及其方法 | |
| US20030068419A1 (en) | Food bar compositions | |
| US20090010993A1 (en) | Composition comprising polyphenol | |
| ES2268632T3 (es) | Composiciones de productos naturales y uso de las mismas. | |
| JP4371431B2 (ja) | 抗アレルギー性組成物 | |
| US10543246B2 (en) | Composition for preventing or treating hyperlipidemia | |
| RU2340337C2 (ru) | Новые нутрицевтические композиции, включающие галлат эпигаллокатехина и кетон малины | |
| US20090011103A1 (en) | Composition comprising polyphenol | |
| JP3110020B2 (ja) | ヘリコバクターピロリの除菌剤 | |
| EP2036445A1 (en) | Nutraceutic preparation in powder form containing free plant sterols | |
| JP2007246449A (ja) | 脂肪分解促進剤及びそれを含有する飲食品並びに飼料 | |
| CN107613994A (zh) | 泌尿器官症状改善剂 | |
| WO2022270616A1 (ja) | 筋損傷抑制用組成物 | |
| CA3030444A1 (en) | Weight loss compound and method of extraction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070627 |